secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2022-11-07T23:59:59+00:00
Accession:  0001628280-22-028535
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Q3 net income $3.2M on $14.5M license; cash $16.9M; AVTX-002 data H1 2023
-------------------------------------------------------------------------------

- Q3 net income of $3.2M vs $17.4M loss in 2021; net revenues $15M including $14.5M license revenue.
- Cash $16.9M at Sep 30 2022, down $37.7M from Dec 31 2021; operating expenses fell $23.6M YTD.
- Agreement to sell net economic rights to legacy out-licensed assets (AVTX-007, -501, -611) for $5M due Nov 2022.
- Phase 2 PEAK trial of AVTX-002 in non-eosinophilic asthma enrollment to complete by end of 2022; topline data H1 2023.
- Pivotal LADDER trial of AVTX-803 in LAD II on track for data in H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828022028535/0001628280-22-028535-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828022028535/avtx-20221107.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-028535

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer